MTHFD1 Regulates the NADPH Redox Homeostasis in MYCN-amplified Neuroblastoma

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Feb 9

PMID 38336749

Authors

Jinqiu Guan

Mengzhen Li

Yi Wang

Yu Zhang

Yi Que

Suying Lu

Juan Wang

Jia Zhu

Junting Huang

Zijun Zhen

FeiFei Sun

Mengjia Song

Yizhuo Zhang

Affiliations

Soon will be listed here.

Abstract

MYCN amplification is an independent poor prognostic factor in patients with high-risk neuroblastoma (NB). Further exploring the molecular regulatory mechanisms in MYCN-amplified NB will help to develop novel therapy targets. In this study, methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) was identified as the differentially expressed gene (DEG) highly expressed in MYCN-amplified NB, and it showed a positive correlation with MYCN and was associated with a poor prognosis of NB patients. Knockdown of MTHFD1 inhibited proliferation and migration, and induced apoptosis of NB cells in vitro. Mouse model experiments validated the tumorigenic effect of MTHFD1 in NB in vivo. In terms of the mechanism, ChIP-qPCR and dual-luciferase reporter assays demonstrated that MTHFD1 was directly activated by MYCN at the transcriptional level. As an important enzyme in the folic acid metabolism pathway, MTHFD1 maintained the NADPH redox homeostasis in MYCN-amplified NB. Knockdown of MTHFD1 reduced cellular NADPH/NADP and GSH/GSSG ratios, increased cellular reactive oxygen species (ROS) and triggered the apoptosis of NB cells. Moreover, genetic knockdown of MTHFD1 or application of the anti-folic acid metabolism drug methotrexate (MTX) potentiated the anti-tumor effect of JQ1 both in vitro and in vivo. Taken together, MTHFD1 as an oncogene is a potential therapeutic target for MYCN-amplified NB. The combination of MTX with JQ1 is of important clinical translational significance for the treatment of patients with MYCN-amplified NB.

Citing Articles

Identifying MTHFD1 and LGALS4 as Potential Therapeutic Targets in Prostate Cancer Through Multi-Omics Mendelian Randomization Analysis.

Han H, Su H, Lv Z, Zhu C, Huang J Biomedicines. 2025; 13(1).

PMID: 39857769 PMC: 11759815. DOI: 10.3390/biomedicines13010185.

Inducing disulfidptosis in tumors:potential pathways and significance.

Mi T, Kong X, Chen M, Guo P, He D MedComm (2020). 2024; 5(11):e791.

PMID: 39415848 PMC: 11480524. DOI: 10.1002/mco2.791.

Defining neuroblastoma: From origin to precision medicine.

Sainero-Alcolado L, Sjoberg Bexelius T, Santopolo G, Yuan Y, Liano-Pons J, Arsenian-Henriksson M Neuro Oncol. 2024; 26(12):2174-2192.

PMID: 39101440 PMC: 11630532. DOI: 10.1093/neuonc/noae152.

Specific association of expressions with small cell lung cancer development and chemoradiotherapy outcome.

Hao Y, Lu R, Guo Y, Bao P Saudi Med J. 2024; 45(8):783-790.

PMID: 39074897 PMC: 11288495. DOI: 10.15537/smj.2024.45.8.20230990.

References

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

Seeger R, Brodeur G, Sather H, Dalton A, Siegel S, Wong K . Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111-6. DOI: 10.1056/NEJM198510313131802. View

Puissant A, Frumm S, Alexe G, Bassil C, Qi J, Chanthery Y . Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3(3):308-23. PMC: 3672953. DOI: 10.1158/2159-8290.CD-12-0418. View

Mazar J, Gordon C, Naga V, Westmoreland T . The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner. Anticancer Agents Med Chem. 2020; 20(13):1613-1625. PMC: 7527568. DOI: 10.2174/1871520620666200424123834. View

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

Reznik E, Luna A, Aksoy B, Liu E, La K, Ostrovnaya I . A Landscape of Metabolic Variation across Tumor Types. Cell Syst. 2018; 6(3):301-313.e3. PMC: 5876114. DOI: 10.1016/j.cels.2017.12.014. View

Sun L, Suo C, Li S, Zhang H, Gao P . Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys Acta Rev Cancer. 2018; 1870(1):51-66. DOI: 10.1016/j.bbcan.2018.06.005. View

Pavlova N, Zhu J, Thompson C . The hallmarks of cancer metabolism: Still emerging. Cell Metab. 2022; 34(3):355-377. PMC: 8891094. DOI: 10.1016/j.cmet.2022.01.007. View

DeBerardinis R, Chandel N . Fundamentals of cancer metabolism. Sci Adv. 2016; 2(5):e1600200. PMC: 4928883. DOI: 10.1126/sciadv.1600200. View

10.

MacFarlane A, Liu X, Perry C, Flodby P, Allen R, Stabler S . Cytoplasmic serine hydroxymethyltransferase regulates the metabolic partitioning of methylenetetrahydrofolate but is not essential in mice. J Biol Chem. 2008; 283(38):25846-53. PMC: 2533799. DOI: 10.1074/jbc.M802671200. View

11.

Fan J, Ye J, Kamphorst J, Shlomi T, Thompson C, Rabinowitz J . Quantitative flux analysis reveals folate-dependent NADPH production. Nature. 2014; 510(7504):298-302. PMC: 4104482. DOI: 10.1038/nature13236. View

12.

Fu C, Sikandar A, Donner J, Zaburannyi N, Herrmann J, Reck M . The natural product carolacton inhibits folate-dependent C1 metabolism by targeting FolD/MTHFD. Nat Commun. 2017; 8(1):1529. PMC: 5688156. DOI: 10.1038/s41467-017-01671-5. View

13.

Chen K, Wu S, Ye S, Huang H, Zhou Y, Zhou H . Dimethyl Fumarate Induces Metabolic Crisie to Suppress Pancreatic Carcinoma. Front Pharmacol. 2021; 12:617714. PMC: 7937954. DOI: 10.3389/fphar.2021.617714. View

14.

Yu H, Wang H, Xu H, Zhang Y, Yu X, Wu M . Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence. Future Oncol. 2019; 15(15):1771-1780. DOI: 10.2217/fon-2018-0606. View

15.

Wang X, Fu X, Zhang J, Xiong C, Zhang S, Lv Y . Identification and validation of mA RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer. Cancer Cell Int. 2020; 20:203. PMC: 7260751. DOI: 10.1186/s12935-020-01283-y. View

16.

Li M, Sun C, Bu X, Que Y, Zhang L, Zhang Y . ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma. Cell Death Dis. 2021; 12(6):620. PMC: 8206128. DOI: 10.1038/s41419-021-03894-3. View

17.

Roy Moulik N, Kumar A, Agrawal S . Folic acid, one-carbon metabolism & childhood cancer. Indian J Med Res. 2017; 146(2):163-174. PMC: 5761026. DOI: 10.4103/ijmr.IJMR_275_15. View

18.

Meng Q, Lu Y, Wei C, Wang Z, Lin J, Liao K . Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis. Oncogene. 2022; 41(32):3912-3924. DOI: 10.1038/s41388-022-02387-7. View

19.

Sdelci S, Rendeiro A, Rathert P, You W, Lin J, Ringler A . MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nat Genet. 2019; 51(6):990-998. PMC: 6952269. DOI: 10.1038/s41588-019-0413-z. View

20.

Xia Y, Ye B, Ding J, Yu Y, Alptekin A, Thangaraju M . Metabolic Reprogramming by MYCN Confers Dependence on the Serine-Glycine-One-Carbon Biosynthetic Pathway. Cancer Res. 2019; 79(15):3837-3850. PMC: 6679782. DOI: 10.1158/0008-5472.CAN-18-3541. View